Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease

Diabetologia

Volumn 62, Issue 7, 2019, Pages 1154-1166

  Heerspink, Hiddo J L ^a   Perco, Paul ^b   Mulder, Skander ^a   Leierer, Johannes ^b   Hansen, Michael K ^c   Heinzel, Andreas ^d   Mayer, Gert ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d Emergentec Biodevelopment GmbH   (Austria)

Author keywords

Biomarkers; Canagliflozin; Chronic kidney disease; Sodium glucose cotransporter 2 inhibitors; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; CANAGLIFLOZIN; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 1; FIBRONECTIN; FIBRONECTIN 1; GLIMEPIRIDE; INTERLEUKIN 6; MATRILYSIN; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL COLLAGENASE; PLACEBO; RANTES; SCATTER FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN A; FN1 PROTEIN, HUMAN;

ADULT; ALBUMINURIA; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG COMPETITION; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG MONITORING; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IC50; KIDNEY FIBROSIS; KIDNEY PROXIMAL TUBULE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRANSCRIPTOMICS; CELL LINE; CHRONIC KIDNEY FAILURE; FIBROSIS; INFLAMMATION; KIDNEY DISEASE; METABOLISM;

BIOMARKERS; CANAGLIFLOZIN; CELL LINE; DIABETES MELLITUS, TYPE 2; FIBRONECTINS; FIBROSIS; HUMANS; INFLAMMATION; INTERLEUKIN-6; KIDNEY DISEASES; MATRIX METALLOPROTEINASE 7; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85064608731     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-019-4859-4     Document Type: Article

References (33)

1. Afkarian M, Sachs MC, Kestenbaum B et al (2013) Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 24(2):302–308. 10.1681/ASN.2012070718
2. Perkovic V, Agarwal R, Fioretto P et al (2016) Management of patients with diabetes and CKD: conclusions from a ‘Kidney Disease: Improving Global Outcomes’ (KDIGO) Controversies Conference. Kidney Int 90(6):1175–1183. 10.1016/j.kint.2016.09.010
3. List JF, Woo V, Morales E, Tang W, Fiedorek FT (2009) Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32(4):650–657. 10.2337/dc08-1863
4. Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V (2017) Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 28(1):368–375. 10.1681/ASN.2016030278
5. Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323–334. 10.1056/NEJMoa1515920
6. Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657. 10.1056/NEJMoa1611925
7. Heerspink HJ, Perkins BA, Fitchett D, Husain M, Cherney D (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 134(10):752–772. 10.1161/CIRCULATIONAHA.116.021887
8. Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E (2017) Characterization and comparison of SGLT2 inhibitors: part 3. Effects on diabetic complications in type 2 diabetic mice. Eur J Pharmacol 809:163–171. 10.1016/j.ejphar.2017.05.019
9. Vallon V, Gerasimova M, Rose MA et al (2014) SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306(2):F194–F204. 10.1152/ajprenal.00520.2013
10. Lambers Heerspink HJ, Oberbauer R, Perco P et al (2015) Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine. Nephrol Dial Transplant 30(Suppl 4):iv105–iiv12. 10.1093/ndt/gfv210
11. Mayer G, Heerspink HJ, Aschauer C et al (2017) Systems biology-derived biomarkers to predict progression of renal function decline in type 2 diabetes. Diabetes Care 40(3):391–397. 10.2337/dc16-2202
12. Cefalu WT, Leiter LA, Yoon KH et al (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 382(9896):941–950. 10.1016/S0140-6736(13)60683-2
13. Devineni D, Curtin CR, Polidori D et al (2013) Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 53(6):601–610. 10.1002/jcph.88
14. Panchapakesan U, Pegg K, Gross S et al (2013) Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy? PLoS One 8(2):e54442. 10.1371/journal.pone.0054442
15. Chen F, Sun Z, Zhu X, Ma Y (2018) Astilbin inhibits high glucose-induced autophagy and apoptosis through the PI3K/Akt pathway in human proximal tubular epithelial cells. Biomed Pharmacother 106:1175–1181. 10.1016/j.biopha.2018.07.072
16. Peruchetti DB, Silva-Aguiar RP, Siqueira GM, Dias WB, Caruso-Neves C (2018) High glucose reduces megalin-mediated albumin endocytosis in renal proximal tubule cells through protein kinase B O-GlcNAcylation. J Biol Chem 293(29):11388–11400. 10.1074/jbc.RA117.001337
17. Fechete R, Heinzel A, Soellner P, Perco P, Lukas A, Mayer B (2013) Using information content for expanding human protein coding gene interaction networks. J Comput Sci Syst Biol 6:2
18. Vallon V (2011) The proximal tubule in the pathophysiology of the diabetic kidney. Am J Physiol Regul Integr Comp Physiol 300(5):R1009–R1022. 10.1152/ajpregu.00809.2010
19. Fox CS, Matsushita K, Woodward M et al (2012) Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 380(9854):1662–1673. 10.1016/S0140-6736(12)61350-6
20. Levey AS, Coresh J, Greene T et al (2007) Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53(4):766–772. 10.1373/clinchem.2006.077180
21. Gohda T, Niewczas MA, Ficociello LH et al (2012) Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 23(3):516–524. 10.1681/ASN.2011060628
22. Niewczas MA, Gohda T, Skupien J et al (2012) Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 23(3):507–515. 10.1681/ASN.2011060627
23. Saulnier PJ, Gand E, Ragot S et al (2014) Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE Cohort. Diabetes Care 37(5):1425–1431. 10.2337/dc13-2580
24. Coca SG, Nadkarni GN, Huang Y et al (2017) Plasma biomarkers and kidney function decline in early and established diabetic kidney disease. J Am Soc Nephrol 28(9):2786–2793. 10.1681/ASN.2016101101
25. Tuttle kR, Brosius F, Adler S (2018) Baricitinib in diabetic kidney disease: results from a phase 2, multi-center, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 33(11):1950–1959. 10.1093/ndt/gfx377
26. Su H, Lei CT, Zhang C (2017) Interleukin-6 signaling pathway and its role in kidney disease: an update. Front Immunol 8:405. 10.3389/fimmu.2017.00405
27. Neelofar K, Ahmad J, Ahmad A, Alam K (2017) Study of IL4-590C/T and IL6-174G/C gene polymorphisms in type 2 diabetic patients with chronic kidney disease in North Indian population. J Cell Biochem 118(7):1803–1809. 10.1002/jcb.25853
28. Rysz J, Banach M, Stolarek RA et al (2007) Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy. J Nephrol 20(4):444–452
29. Ban CR, Twigg SM, Franjic B et al (2010) Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction. Diabetes Res Clin Pract 87(3):335–341. 10.1016/j.diabres.2010.01.004
30. Gilbert RE (2016) SGLT2 inhibitors: beta blockers for the kidney? Lancet Diabetes Endocrinol 4(10):814. 10.1016/S2213-8587(16)30237-6
31. Dekkers CCJ, Petrykiv S, Laverman GD, Cherney D, Gansevoort R, Heerspink HJ (2017) Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. J Am Soc Nephro 28(S1):60
32. Ju W, Nair V, Smith S et al (2015) Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker. Sci Transl Med 7(316):316ra193. 10.1126/scitranslmed.aac7071
33. Jardine MJ, Mahaffey KW, Neal B et al (2017) The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 46(6):462–472. 10.1159/000484633